Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study.

Trial Profile

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study.

Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Ethosuximide (Primary) ; Lamotrigine; Valproic acid
  • Indications Absence epilepsy
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Sep 2017 Results assessing pretreatment problems and differential effects of initial therapy in children with childhood absence epilepsy published in the Neurology
    • 03 Feb 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top